Related Experiment Videos

[Antibacterial activity of fosfomycin in chronic kidney infections]

Minerva Medica
|December 1, 1978
PubMed

Insights

Fosfomycin effectively inhibits common urinary bacteria like Proteus, E. coli, and P. aeruginosa in vitro. In vivo studies confirm its excellent therapeutic action for recurrent urinary infections and chronic pyelonephritis (CPN) associated with kidney stones.

Area of Science:

  • Microbiology
  • Pharmacology
  • Urology

Background:

  • Chronic pyelonephritis (CPN) associated with kidney stones presents a significant clinical challenge.
  • Bacterial resistance and efficacy of antibiotics in complex urinary tract infections require ongoing investigation.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of various antibiotics against bacteria implicated in CPN and kidney stones.
  • To assess the in vivo therapeutic efficacy of fosfomycin in treating recurrent urinary tract infections and CPN, particularly when associated with kidney stones.

Main Methods:

  • Retrospective in vitro analysis of bacterial isolates (Proteus, E. coli, P. aeruginosa) from renal parenchyma and stones.
  • Prospective in vivo study evaluating fosfomycin's clinical outcomes in patients with recurrent UTIs and CPN.

Main Results:

  • Fosfomycin demonstrated broad-spectrum inhibition against tested bacteria across a wide concentration range (50-1000 µg/ml).
  • In vivo, fosfomycin showed excellent efficacy in recurrent urinary infections and very good results in CPN, including cases linked to kidney stones.

Conclusions:

  • Fosfomycin exhibits potent in vitro activity against key uropathogens.
  • Fosfomycin is a highly effective therapeutic option for managing recurrent urinary tract infections and chronic pyelonephritis, even in the presence of kidney stones.

Related Concept Videos